Welcome to our dedicated page for SHUTTLE PHARMACTCLS HLDGS news (Ticker: SHPH), a resource for investors and traders seeking the latest updates and insights on SHUTTLE PHARMACTCLS HLDGS stock.
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) generates news at the intersection of oncology drug development and artificial intelligence–driven molecular discovery. Public updates highlight the company’s efforts to improve outcomes for cancer patients treated with radiation therapy, as well as its ownership and deployment of the Molecule.ai platform, a pharmaceutical software AI-driven system for molecular discovery and early-stage drug development.
Recent news releases describe several key themes. Shuttle Pharma has reported on its historical Phase II clinical trial of Ropidoxuridine (IPdR) in glioblastoma patients undergoing radiation therapy, including enrollment progress and tolerability data, and later on its decision to discontinue those clinical trials and initiate winddown activities in coordination with its contract research organization and clinical sites. These items provide context on the evolution of the company’s oncology pipeline and its strategic reassessment of clinical programs.
Another major news focus is the acquisition and integration of Molecule.ai. Press releases and 8-K filings detail a binding term sheet, asset purchase agreement and closing of the transaction under which a Shuttle Pharma subsidiary acquired substantially all of the assets and liabilities of the Canadian AI company operating Molecule.ai. Coverage explains how the platform supports molecular property prediction, drug-target interaction modeling, cross-property evaluation and structured reasoning, and how Shuttle Pharma aims to use these capabilities to augment its drug discovery and development activities.
News items also address capital markets and regulatory developments, such as a private placement involving a pre-funded warrant, related S-1 and S-1/A registration statements for resale of the underlying shares, and communications regarding Nasdaq listing requirements and a reverse stock split undertaken as part of a compliance initiative. Together, these disclosures offer investors and observers a view into SHPH’s scientific programs, AI platform strategy, financing transactions and listing status.
For readers following SHPH news, the company’s updates provide ongoing insight into its transition from a radiation-sensitizer–focused clinical-stage pharmaceutical profile toward a combined biotechnology and AI-driven molecular discovery business model.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) has published research detailing novel prostate cancer cell lines derived from African American men aimed at enhancing precision medicine. This work, part of a NIH-funded 'Moonshot' project, addresses significant health disparities in prostate cancer within this demographic. The research is expected to facilitate studies on cancer biology and drug effectiveness. The initiative underscores the company's commitment to improving cancer treatment outcomes for African American patients.
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) provided a corporate update following its quarterly report for Q3 2022. Highlights include an IPO raising $10 million, along with an additional $1.5 million from an overallotment option. The company announced an agreement with TCG GreenChem to manufacture its lead drug candidate, Ropidoxuridine, aimed at enhancing cancer treatment outcomes through radiation therapy. Shuttle Pharma also engaged Theradex Oncology for clinical study preparations and received patents in the U.S. and Hong Kong for its HDAC inhibitor technology.
Shuttle Pharmaceuticals Holdings (SHPH) announced its collaboration with Theradex Oncology to prepare for a Phase II clinical study of Ropidoxuridine, an innovative cancer treatment aimed at enhancing the efficacy of radiation therapy (RT). The IND application is expected to be submitted to the FDA by Q2 2023. Ropidoxuridine, designed to improve patient outcomes in glioblastoma treatment, has received orphan-drug designation from the FDA. The market for radiation sensitizers is projected to exceed $4 billion, with expected growth in patient numbers and treatment effectiveness.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) announced the appointment of Dr. Bette Jacobs to its Board of Directors on November 1, 2022. Dr. Jacobs will serve on the Audit and Nominating Committees, bringing extensive experience in healthcare system design, equity, and diversity. She is a professor at Georgetown University and has held various leadership positions, including dean and vice president at Honda of America Manufacturing. Dr. Jacobs expressed her commitment to enhancing the company's mission of improving cancer treatment outcomes.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) announced a partnership with TCG GreenChem, Inc. to manufacture Ropidoxuridine, its lead clinical sensitizer drug candidate. This agreement aims to facilitate the formulation of Ropidoxuridine for clinical trials targeting brain tumors, sarcomas, and pancreatic cancers. The FDA has granted orphan-drug designation for Ropidoxuridine in glioblastoma treatment. The agreement also includes process research and optimization to enhance drug development. The market for radiation sensitizers is projected to exceed $4.0 billion due to a growing patient base.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has received patents in the U.S. and Hong Kong for its HDAC inhibitor technology, aimed at enhancing radiation therapy outcomes for cancer patients. This innovation targets over 800,000 U.S. patients undergoing radiation, with a projected market exceeding $4 billion annually. The company is focused on building its drug candidate portfolio to improve patient quality of life and treatment efficacy.
CEO Anatoly Dritschilo emphasized the goal of being at the forefront of cancer treatment advancements with selective HDAC6 inhibitors.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) announced the successful closing of its initial public offering (IPO) on September 6, 2022. The company sold 1,225,888 units at a public offering price of $8.125 per unit, raising approximately $9,960,340 before expenses. Each unit comprises one share of common stock and a warrant for one additional share, exercised at $0.01 each. The stock began trading on the Nasdaq on August 31, 2022. Boustead Securities, LLC acted as lead underwriter for the offering.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) has commenced trading on The Nasdaq Capital Market. The company focuses on developing sensitizers to enhance the efficacy of radiation therapy for cancer patients while minimizing side effects. Their lead product candidate, Ropidoxuridine, has completed a Phase I clinical trial. Shuttle Pharma aims to address serious needs in treating brain tumors, sarcomas, and pancreatic cancers. The company is positioned to progress its innovative therapy pipeline and deliver new treatments for patients lacking effective options.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) has priced its initial public offering (IPO) at $8.125 per unit, raising gross proceeds of $9,960,340. The offering consists of 1,225,888 units, each including one share of common stock and a warrant to purchase an additional share at $0.01. The company's common stock is set to begin trading on the Nasdaq Capital Market on August 31, 2022. Boustead Securities, LLC is the lead underwriter for the offering, which is expected to close on September 2, 2022, subject to customary conditions.